Agilent Secures FDA Nod for PD-L1 Diagnostic in Esophageal Cancer
Event summary
- Agilent's PD-L1 IHC 22C3 pharmDx received FDA approval as a companion diagnostic for esophageal or gastroesophageal junction (GEJ) carcinoma patients eligible for Merck's KEYTRUDA.
- This marks the eighth FDA-approved indication for the diagnostic in conjunction with KEYTRUDA.
- The diagnostic identifies patients with tumors expressing PD-L1 (CPS ≥ 1) for potential KEYTRUDA treatment.
- Esophageal cancer caused approximately 16,250 deaths in the U.S. in 2025, with a 5-year survival rate of 21.9%.
- Agilent developed the diagnostic in partnership with Merck.
The big picture
Agilent's FDA approval strengthens its position in the precision medicine space, particularly in oncology diagnostics. The approval aligns with the broader trend of personalized cancer treatments, where companion diagnostics play a crucial role in identifying patient subsets likely to benefit from specific therapies. This approval also underscores the strategic importance of Agilent's partnership with Merck, reinforcing their combined efforts to advance targeted cancer therapies.
What we're watching
- Market Expansion
- How Agilent will leverage this approval to expand its diagnostic portfolio in oncology.
- Partnership Dynamics
- Whether the Agilent-Merck collaboration will yield further regulatory successes.
- Competitive Positioning
- The pace at which competitors develop similar companion diagnostics for esophageal cancer.
Related topics